BACKGROUND: Multiple studies have reported the prognostic impact of DNA methylation changes in acute myeloid leukemia (AML). However, these epigenetic markers have not been thoroughly validated and therefore are still not considered in clinical practice. Hence, we aimed to independently verify results of selected studies describing the relationship between DNA methylation of specific genes and their prognostic potential in predicting overall survival (OS) and event-free survival (EFS). RESULTS: Fourteen studies (published 2011-2019) comprising of 27 genes were subjected to validation by a custom NGS-based sequencing panel in 178 newly diagnosed non-M3 AML patients treated by 3 + 7 induction regimen. The results were considered as successfully validated, if both the log-rank test and multivariate Cox regression analysis had a p-value ≤ 0.05. The predictive role of DNA methylation was confirmed for three studies comprising of four genes: CEBPA (OS: p = 0.02; EFS: p = 0.03), PBX3 (EFS: p = 0.01), LZTS2 (OS: p = 0.05; EFS: p = 0.0003), and NR6A1 (OS: p = 0.004; EFS: p = 0.0003). For all of these genes, higher methylation was an indicator of longer survival. Concurrent higher methylation of both LZTS2 and NR6A1 was highly significant for survival in cytogenetically normal (CN) AML group (OS: p < 0.0001; EFS: p < 0.0001) as well as for the whole AML cohort (OS: p = 0.01; EFS < 0.0001). In contrast, for two studies reporting the poor prognostic effect of higher GPX3 and DLX4 methylation, we found the exact opposite, again linking higher GPX3 (OS: p = 0.006; EFS: p < 0.0001) and DLX4 (OS: p = 0.03; EFS = 0.03) methylation to a favorable treatment outcome. Individual gene significance levels refer to the outcomes of multivariate Cox regression analysis. CONCLUSIONS: Out of twenty-seven genes subjected to DNA methylation validation, a prognostic role was observed for six genes. Therefore, independent validation studies are necessary to reveal truly prognostic DNA methylation changes and to enable the introduction of these promising epigenetic markers into clinical practice.

Department of Genomics Institute of Hematology and Blood Transfusion U Nemocnice 1 128 20 Prague 2 Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic

Faculty of Science Charles University Prague Czech Republic

Institute of Clinical and Experimental Hematology 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Handschuh L. Not only mutations matter: molecular picture of acute myeloid leukemia emerging from transcriptome studies. J Oncol. 2019;30(2019):7239206. PubMed PMC

Rockova V, Abbas S, Wouters BJ, Erpelinck CA, Beverloo HB, Delwel R, et al. Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood. 2011;118(4):1069–1076. doi: 10.1182/blood-2011-02-334748. PubMed DOI

Jiang H, Ou Z, He Y, Yu M, Wu S, Li G, et al. DNA methylation markers in the diagnosis and prognosis of common leukemias. Signal Transduct Target Ther. 2020;5(1):1–10. doi: 10.1038/s41392-019-0089-y. PubMed DOI PMC

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi: 10.1182/blood-2016-08-733196. PubMed DOI PMC

Sestakova S, Salek C, Remesova H. DNA methylation validation methods: a coherent review with practical comparison. Biol Proced. 2019;21:1–11. doi: 10.1186/s12575-018-0089-2. PubMed DOI PMC

Gosselt HR, Griffioen PH, van Zelst BD, Oosterom N, de Jonge R, Heil SG. Global DNA (hydroxy)methylation is stable over time under several storage conditions and temperatures. Epigenetics. 2021;16(1):45–53. doi: 10.1080/15592294.2020.1786318. PubMed DOI PMC

Yang X, Wong MPM, Ng RK. Aberrant DNA methylation in acute myeloid leukemia and its clinical implications. Int J Mol Sci. 2019 doi: 10.3390/ijms20184576. PubMed DOI PMC

Hajkova H, Markova J, Haskovec C, Sarova I, Fuchs O, Kostecka A, et al. Decreased DNA methylation in acute myeloid leukemia patients with DNMT3A mutations and prognostic implications of DNA methylation. Leuk Res. 2012;36(9):1128–1133. doi: 10.1016/j.leukres.2012.05.012. PubMed DOI

Guo H, Zhang TJ, Wen XM, Zhou JD, Ma JC, An C, et al. Hypermethylation of secreted frizzled-related proteins predicts poor prognosis in non-M3 acute myeloid leukemia. Onco Targets Ther. 2017;20(10):3635–3644. doi: 10.2147/OTT.S136502. PubMed DOI PMC

Hajkova H, Fritz MH, Haskovec C, Schwarz J, Salek C, Markova J, et al. CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients. J Hematol Oncol. 2014;7:66014–66664. doi: 10.1186/s13045-014-0066-4. PubMed DOI PMC

Jost E, Lin Q, Weidner CI, Wilop S, Hoffmann M, Walenda T, et al. Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia. Leukemia. 2014;28(6):1227–1234. doi: 10.1038/leu.2013.362. PubMed DOI PMC

Li XX, Zhou JD, Zhang TJ, Yang L, Wen XM, Ma JC, et al. Epigenetic dysregulation of NKD2 is a valuable predictor assessing treatment outcome in acute myeloid leukemia. J Cancer. 2017;8(3):460–468. doi: 10.7150/jca.16914. PubMed DOI PMC

Lin TC, Hou HA, Chou WC, Ou DL, Yu SL, Tien HF, et al. CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia. Leukemia. 2011;25(1):32–40. doi: 10.1038/leu.2010.222. PubMed DOI

Liu F, Gong M, Gao L, Cai X, Zhang H, Ma Y. RASSF1A hypermethylation is associated with ASXL1 mutation and indicates an adverse outcome in non-M3 acute myeloid leukemia. Onco Targets Ther. 2017;22(10):4143–4151. doi: 10.2147/OTT.S142528. PubMed DOI PMC

Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, et al. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol. 2014;32(6):548–556. doi: 10.1200/JCO.2013.50.6337. PubMed DOI PMC

Qu X, Othus M, Davison J, Wu Y, Yan L, Meshinchi S, et al. Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials. Cancer. 2017;123(13):2472–2481. doi: 10.1002/cncr.30626. PubMed DOI PMC

Sestakova S, Krejcik Z, Folta A, Cerovska E, Salek C, Merkerova MD, et al. DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations. Cancer Biomark. 2019;25(1):43–51. doi: 10.3233/CBM-182176. PubMed DOI

Treppendahl MB, Qiu X, Sogaard A, Yang X, Nandrup-Bus C, Hother C, et al. Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood. 2012;119(1):206–216. doi: 10.1182/blood-2011-06-362541. PubMed DOI PMC

Zhou JD, Yao DM, Zhang YY, Ma JC, Wen XM, Yang J, et al. GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia. Am J Cancer Res. 2015;5(5):1786–1794. PubMed PMC

Zhou JD, Zhang TJ, Wang YX, Yang DQ, Yang L, Ma JC, et al. DLX4 hypermethylation is a prognostically adverse indicator in de novo acute myeloid leukemia. Tumour Biol. 2016;37(7):8951–8960. doi: 10.1007/s13277-015-4364-4. PubMed DOI

Bozic T, Lin Q, Frobel J, Wilop S, Hoffmann M, Muller-Tidow C, et al. DNA-methylation in C1R is a prognostic biomarker for acute myeloid leukemia. Clin Epigenetics. 2015;7:116015–201536. doi: 10.1186/s13148-015-0153-6. PubMed DOI PMC

Morgan R, Pandha HS. PBX3 in Cancer. Cancers (Basel) 2020;12:2. doi: 10.3390/cancers12020431. PubMed DOI PMC

Chang C, Worley BL, Phaeton R, Hempel N. Extracellular glutathione peroxidase GPx3 and its role in cancer. Cancers (Basel) 2020;12:8. doi: 10.3390/cancers12082197. PubMed DOI PMC

Pelosof L, Yerram S, Armstrong T, Chu N, Danilova L, Yanagisawa B, et al. GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer. Epigenetics. 2017;12(7):540–550. doi: 10.1080/15592294.2016.1265711. PubMed DOI PMC

Sun G, Ge Y, Zhang Y, Yan L, Wu X, Ouyang W, et al. Transcription factors BARX1 and DLX4 contribute to progression of clear cell renal cell carcinoma via promoting proliferation and epithelial-mesenchymal transition. Front Mol Biosci. 2021;8:626328. doi: 10.3389/fmolb.2021.626328. PubMed DOI PMC

Zhang L, Wan Y, Jiang Y, Zhang Z, Shu S, Cheng W, et al. Overexpression of BP1, an isoform of homeobox gene DLX4, promotes cell proliferation, migration and predicts poor prognosis in endometrial cancer. Gene. 2019;30(707):216–223. doi: 10.1016/j.gene.2019.05.028. PubMed DOI

Zhou JD, Yang J, Guo H, Deng ZQ, Wen XM, Yang L, et al. BP1 overexpression is associated with adverse prognosis in de novo acute myeloid leukemia. Leuk Lymphoma. 2016;57(4):828–834. doi: 10.3109/10428194.2015.1088648. PubMed DOI

Hollington P, Neufing P, Kalionis B, Waring P, Bentel J, Wattchow D, et al. Expression and localization of homeodomain proteins DLX4, HB9 and HB24 in malignant and benign human colorectal tissues. Anticancer Res. 2004;24(2B):955–962. PubMed

Ferrara F, Vitagliano O. Induction therapy in acute myeloid leukemia: is it time to put aside standard 3 + 7? Hematol Oncol. 2019;37(5):558–563. doi: 10.1002/hon.2615. PubMed DOI

Andrews S. FastQC: a quality control tool for high throughput sequence data [Online]. 2015. Available at: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/. Accessed 20 June 2020.

Ewels P, Magnusson M, Lundin S, Kaller M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016;32(19):3047–3048. doi: 10.1093/bioinformatics/btw354. PubMed DOI PMC

Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011;17(1):10–12. doi: 10.14806/ej.17.1.200. DOI

Otto C, Stadler PF, Hoffmann S. Fast and sensitive mapping of bisulfite-treated sequencing data. Bioinformatics. 2012;28(13):1698–1704. doi: 10.1093/bioinformatics/bts254. PubMed DOI

Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–365. doi: 10.1182/blood-2009-11-254441. PubMed DOI

Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE. 2012;7(12):e51862. doi: 10.1371/journal.pone.0051862. PubMed DOI PMC

Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. New England Journal of Medicine. 2013;368(22):2059–2074. doi: 10.1056/NEJMoa1301689. PubMed DOI PMC

MethScore as a new comprehensive DNA methylation-based value refining the prognosis in acute myeloid leukemia